The landmark 2022 US FDA regulatory approval of selpercatinib, a RET selective tyrosine kinase inhibitor (TKI), represented the seventh tissue-agnostic indication in oncology [1], following tumor site-specific approvals of selpercatinib for non-small cell lung cancer (NSCLC) and thyroid cancer. The gene discussed is RET; the disease is neoplasm.